Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 18:6:35314.
doi: 10.1038/srep35314.

Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy

Chihiro Fujii  1 , Takayuki Kondo  1   2   3   4 , Hirofumi Ochi  5 , Yoichiro Okada  3 , Yuichiro Hashi  3 , Tetsuya Adachi  6   7 , Masaharu Shin-Ya  6 , Sadayuki Matsumoto  4 , Ryosuke Takahashi  3 , Masanori Nakagawa  8 , Toshiki Mizuno  1
Affiliations

Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy

Chihiro Fujii et al. Sci Rep. .

Abstract

Multiple sclerosis (MS) is a T cell-mediated autoimmune disease. Fingolimod, a highly effective disease-modifying drug for MS, retains CCR7+ central memory T cells in which autoaggressive T cells putatively exist, in secondary lymphoid organs, although relapse may still occur in some patients. Here, we analyzed the T cell phenotypes of fingolimod-treated, fingolimod-untreated patients, and healthy subjects. The frequency of CD56+ T cells and granzyme B-, perforin-, and Fas ligand-positive T cells significantly increased during fingolimod treatment. Each T cell subpopulation further increased during relapse. Interestingly, T cells from fingolimod-treated patients exhibited interferon-γ biased production, and more myelin basic protein-reactive cells was noted in CD56+ than in CD56- T cells. It is likely that the altered T cell phenotypes play a role in MS relapse in fingolimod-treated patients. Further clinical studies are necessary to investigate whether altered T cell phenotypes are a biomarker for relapse under fingolimod therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Frequency of CD56+ T cells in healthy subjects (HS) and patients with multiple sclerosis (MS).
(a) CD56 expression on CD3-gated T cells. Representative FACS dot plots of HS, MS patients without disease-modifying drug (MS without DMD), MS patients with IFN-β therapy (MS with IFN-β), and those with fingolimod therapy (MS with fingolimod) are shown. (b) The frequency of CD56+ cells in CD3+ T cells in the indicated groups. (c) The frequency of CD56+ cells in CD4+ T cells in the indicated groups (left), and that of CD56+ cells in CD8+ T cells in the indicated groups (right). (d) The frequency of CD56+ T cells before and after fingolimod treatment in MS patients. The frequency of CD56+ T cells within total T cells, and CD4+ and CD8+ T cell subsets is shown. nF-MS: multiple sclerosis patients without fingolimod therapy, F-MS: multiple sclerosis patients with fingolimod therapy, rem: remission, rel: relapse, rel-free: relapse-free. Bars represent median values. p-values: *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 2
Figure 2. Association of CD56 and CCR7 expression on T cells in healthy subjects (HS) and multiple sclerosis (MS) patients.
(a) The frequency of CCR7+ T cells within CD3+ T cells in F-MS patients both in remission and at relapse. (b) The frequency of central memory T cells (CCR7+CD45RA− T cells) within CD3+, CD4+ or CD8+ T cells in F-MS patients both in remission and at relapse. (c) The frequency of CCR7− T cells within CD56+ T cells in HS and each patient group. (d) The frequency of CD56+ cells within CCR7− and CCR7+ T cells. (e) The frequency of CD56+ cells within naïve (CCR7+CD45RA+), central memory (CCR7+CD45RA−) (TCM), effector memory (CCR7−CD45RA−) (TEM) and CD45RA+ TEM (TEMRA) subsets in CD4+ and CD8+ T cells. nF-MS: multiple sclerosis patients without fingolimod therapy, F-MS: multiple sclerosis patients with fingolimod therapy, rem: remission, rel: relapse, rel-free: relapse-free. Bars represent median values. p-values: *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 3
Figure 3. Effect of fingolimod, fingolimod-phosphate and the serums of patients under fingolimod therapy on CD56 expression in vitro.
(a) Kinetic change of CD56+ T cells co-cultured with fingolimod (F) or fingolimod-phosphate (F-p) for 5 days in healthy subjects (HS) and multiple sclerosis patients without disease-modifying drug (MS without DMD). (b) CD56 expression on T cells stimulated by PHA in the presence or absence of fingolimod or fingolimod phosphate at a concentration of 0.1 and 1 μM. Representative graphs of CD56 expression on T cells cultured in the presence of PHA, PHA with 0.1 μM fingolimod and PHA with 0.1 μM fingolimod-phosphate (left panel) (c) CD56 expression on T cells of MS without DMD co-cultured with serum of the same patient after fingolimod therapy. Each column represents mean ± SEM. p-values: *p < 0.05.
Figure 4
Figure 4. Expression of cytotoxic molecules in each T cell subset of healthy subjects (HS) and multiple sclerosis (MS) patients.
(a) Representative analysis of CD56 and granzyme B expression, gated on CD3+ T cells from left to right: a healthy subject, an MS patient not on fingolimod in remission (nF-MS rem) and one at relapse (nF-MS rel), a relapse-free MS patient with fingolimod therapy (rel-free F-MS) and one at relapse (F-MS rel). (b) The expression of granzyme B (GrzB), perforin, and Fas-Ligand (FasL) in or on CD3+ T cells are shown. (c) The frequency of cells expressing each cytotoxic molecule was compared between CD56+ and CD56− T cells. (d) The frequency of cells expressing each cytotoxic molecule in CD4+CD56+ T cells, CD4+CD56− T cells, CD8+CD56+ T cells, and CD8+CD56− T cells. Bars represent median values. Each column represents mean ± SEM. p-values: *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 5
Figure 5. The frequency of proinflammatory cytokine-producing cells in response to PMA/ionomycin stimulation.
(a) Representative data of FACS dot plots analyzing IFN-γ and IL-17A production gated on CD3+ T cells. Depicted as follows from left to right, a healthy subject (HS), a multiple sclerosis (MS) patient not on fingolimod in remission (nF-MS rem) and one at relapse (nF-MS rel), and a relapse-free patient with fingolimod therapy (rel-free F-MS) and one at relapse (F-MS rel). (b) The frequency of IL-17A-producing cells in CD3+ T cells (left) and that of IFN-γ-producing cells in CD3+ T cells (right). (c) The frequency of IFN-γ producing cells was compared between CD56+ and CD56− T cells. (d) The frequency of IFN-γ-producing cells in CD4+CD56+ T cells and CD4+CD56− T cells, CD8+CD56+ T cells and CD8+CD56− T cells. Bars represent median values. Each column represents mean ± SEM. P-values: *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 6
Figure 6. Myelin basic protein (MBP)-reactive proinflammatory cytokine production by CD56+ T cells from multiple sclerosis (MS) patients on fingolimod in remission.
CD56+ and CD56− T cells were co-cultured with antigen-presenting cells (APC) in the presence or absence of MBP peptide mixture, and intracellular cytokines were analyzed by flow cytometry. (a) Representative FACS dot plots of IFN-γ-producing cells in CD56+ and CD56− T cells when the cells were co-cultured with APC in the presence or absence of MBP. (b) The delta frequency of cells that produced IFN-γ (upper row) and IL-17A (bottom row) within CD56+ and CD56− T cells. The delta frequency was calculated by subtracting the frequency of cytokine-producing cells in the absence of MBP from that in the presence of MBP. Diamonds are data from relapse-experienced MS patients with fingolimod therapy in remission, and circles represent relapse-free MS patients while on fingolimod treatment. Bars represent median values. p-values: **p < 0.01.
Figure 7
Figure 7. Longitudinal analysis of CD56 expression, granzyme B (GrzB) expression, and frequency of IFN-γ-producing cells in relapse-experienced multiple sclerosis (MS) patients on fingolimod.
(a) Temporal changes in the frequency of CD56-expressing cells within the CD3+ T cell fraction. (b) The frequency of GrzB-expressing cells and IFN-γ-producing cells in CD56+ and CD56− T cell subsets decreased 3 months after relapse. (c) The frequency of CD56 expression in relapse-experienced MS patients with fingolimod therapy in remission remained higher than in patients who did not have any relapse while on fingolimod treatment. Each relapse-experienced patient is indicated by different-shaped dots. The frequencies at relapse are presented as red dots, and those in remission are presented as black dots. Bars represent median values. p-values: **p < 0.01.
Figure 8
Figure 8. The frequency of Foxp3+ regulatory T cells in multiple sclerosis patients and healthy subjects.
The frequency of regulatory T cells (Treg cells: CD3+CD4+CD25+Foxp3+ cells) in CD3+ T cells (upper) and CD4+ T cells (bottom). HS: healthy subjects, nF-MS: multiple sclerosis patients without fingolimod therapy, F-MS: multiple sclerosis patients with fingolimod therapy, rem: remission, rel: relapse, rel-free: relapse-free. Bars represent median values. p-values: *p < 0.05; **p < 0.01.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sospedra M. & Martin R. Immunology of multiple sclerosis. Annual review of immunology 23, 683–747 (2005). - PubMed
    1. Axtell R. C. et al.. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nature medicine 16, 406–412 (2010). - PMC - PubMed
    1. Sallusto F. et al.. T-cell trafficking in the central nervous system. Immunological reviews 248, 216–227 (2012). - PubMed
    1. Steinman L. Immunology of relapse and remission in multiple sclerosis. Annual review of immunology 32, 257–281 (2014). - PubMed
    1. Brinkmann V. et al.. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nature reviews. Drug discovery 9, 883–897 (2010). - PubMed

MeSH terms